Logotype for Perrigo Company plc

Perrigo Company (PRGO) Q1 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Perrigo Company plc

Q1 2025 earnings summary

9 Jul, 2026

Executive summary

  • Delivered strong Q1 2025 results with adjusted EPS up 106.9% to $0.60, robust margin expansion, and 19% year-over-year growth in infant formula net sales, supported by cost initiatives and Project Energize savings.

  • Net sales declined 3.5% year-over-year to $1.04 billion, mainly due to divestitures, currency impacts, and lower sales in Digestive and Women's Health, but organic net sales grew 1.8% excluding lost distribution and prior year Opill/Women's Health stocking.

  • Advanced the 3S plan (stabilize, streamline, strengthen), with new business awards offsetting prior losses in U.S. store brand OTC and improved service levels to 94%.

  • Project Energize and supply chain reinvention delivered $8M and $20M in annual savings, with Energize reaching a $159M annual run rate.

  • International business posted mid-single digit sales growth and double-digit profit growth, now accounting for over 40% of global sales.

Financial highlights

  • Net sales: $1,043.9 million, down 3.5% year-over-year; organic net sales down 0.4%, but up 1.8% excluding lost distribution and prior year Opill sell-in.

  • Adjusted gross margin expanded 440 bps to 41.0%; reported gross margin increased 450 bps to 37.6%.

  • Adjusted operating income rose 57.6% to $147M; reported operating income was $47M, up from a $55M loss prior year.

  • Adjusted EPS: $0.60 (up 106.9% year-over-year); adjusted net income was $83M, up from $40M.

  • Cash and cash equivalents at quarter-end: $410M; Q1 operating cash outflow was $65M, mainly due to inventory rebuild, litigation, and restructuring.

Outlook and guidance

  • Fiscal 2025 reported net sales growth target widened to 0%–3%; organic net sales growth target widened to 1.5%–4.5%, reflecting macro uncertainty and tariff impacts.

  • Reaffirmed adjusted EPS target of $2.90–$3.10 for 2025 and net leverage target of ~3.5x by year-end.

  • Expect 2025 earnings phasing to be 40% in H1 and 60% in H2, with significant ramp in infant formula sales in the second half.

  • Project Energize expected to deliver $140–$170M in annualized pre-tax savings by 2026; supply chain and efficiency programs to provide $200–$300M annual run-rate savings by 2028.

  • Midterm 2027 targets reaffirmed.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Perrigo Company